Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults

Vaccine

Volumn 32, Issue 13, 2014, Pages 1507-1513

  Hens, Niel ^a,b   Habteab Ghebretinsae, Aklilu ^b   Hardt, Karin ^c   Van Damme, Pierre ^a   Van Herck, Koen ^a,d  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c GSK   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

Changepoint model; Immunogenicity assay; Long term follow up; Longitudinal data analysis; Vaccine trials

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SERODIAGNOSIS; STATISTICAL MODEL; VACCINATION; YOUNG ADULT;

CHANGEPOINT MODEL; IMMUNOGENICITY ASSAY; LONG TERM FOLLOW-UP; LONGITUDINAL DATA ANALYSIS; VACCINE TRIALS;

ADOLESCENT; ADULT; ANTIBODY FORMATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION, SECONDARY; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84896715295     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.088     Document Type: Article

References (25)

1. World Health Organization WHO position paper on hepatitis A vaccines - June 2012. Wkly Epidemiol Rec 2012, 87:261-276.
2. Rein D.B., Stevens G.A., Wiersma S. Modeling the global burden of hepatitis A virus infections in 1990 and 2005. Hepatology 2011, 54(Suppl. 1):1178A-1179A.
3. Hollinger F.B., Ticehurst J.R. Hepatitis A virus. Fields virology 1996, 735-782. Lippincott-Raven, Philadelphia. 3rd ed. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
4. Hammitt L.L., Bulkow L., Hennessy T.W., Zanis C., Snowball M., Williams J.L., et al. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis 2008, 198:1776-1782.
5. Bovier P.A., Bock J., Ebengo T.F., Frösner G., Glaus J., Herzog C., et al. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. J Med Virol 2010, 82:1629-1634.
6. Bovier P.A., Bock J., Loutan L., Farinelli T., Glueck R., Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 2002, 68:489-493.
7. Rendi-Wagner P., Korinek M., Winkler B., Kundi M., Kollaritsch H., Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 2007, 25:927-931.
8. Van Herck K., Beutels P., Van Damme P., Beutels M., Van den Dries J., Briantais P., et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 2000, 60:1-7.
9. Van Herck K., Jacquet J.M., Van Damme P. Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. J Med Virol 2011, 83:1885-1891.
10. Van Herck K., Crasta P.D., Messier M., Hardt K., Van Damme P. Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Hum Vaccin Immunother 2012, 8:323-327.
11. Van Herck K., Van Damme P., Hoet B. Two-dose inactivated hepatitis A vaccine: follow-up data 10 year after immunisation confirm model-based estimates of antibody persistence over 25 years. 9th Conference of the International Society for Travel Medicine (CISTM) 1-5 May 2005, 108. Abstract Book (PO02.06).
12. Van Herck K., Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001, 63:1-7.
13. Van Herck K., Renard D., Molenberghs G., Van Damme P. Model-based estimates on long-term persistence of vaccine-induced hepatitis A antibodies. Proceedings of the 10th international symposium on viral hepatitis and liver disease 2002, 56-59. International Medical Press, Atlanta, GA. H.S. Margolis, M.J. Alter, J.T. Liang, J.L. Dienstag (Eds.).
14. Van Damme P., Cramm M., Thoelen S., De Groote K., Safary A., Meheus A. Inactivated hepatitis A: reactogenicity, immunogenicity and long term antibody persistence. J Med Virol 1994, 44:446-451.
15. Andraud M., Lejeune O., Musoro J.Z., Ogunjimi B., Beutels P., Hens N. Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis A virus. PLoS Comput Biol 2012, 8:e1002418.
16. Amanna I.J., Slifka M.K. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010, 236:125-138.
17. Verbeke G., Molenberghs G. Linear mixed models for longitudinal data 2000, Springer Verlag, New York. 1st ed.
18. Willmott C.J. On the validation of models. Phys Geogr 1981, 2:184-194.
19. Raczniak G.A., Bulkow L.R., Bruce M.G., Zanis C.L., Baum R.L., Snowball M.M., et al. Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series. J Infect Dis 2013, 207:493-496.
20. Fan P.C., Chang M.H., Lee P.I., Safary A., Lee C.Y. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine 1998, 16:232-235.
21. Van Damme P., Banatvala J., Fay O., Iwarson S., McMahon B., Van Herck K., et al. Hepatitis A booster vaccination: is there a need?. Lancet 2003, 362:1065-1071.
22. Van Herck K., Van Damme P., Lievens M., Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol 2004, 72:194-196.
23. Cederna J.B., Klinzman D., Stapleton J.T. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin inactivated hepatitis A vaccine. Vaccine 1999, 18:892-898.
24. Kanra G., Yalcin S.S., Kara A., Ozmert E., Yurdakok K. Hepatitis A booster vaccine in children after infant immunization. Pediatr Infect Dis J 2002, 21:727-730.
25. Hatz C., van der Ploeg R., Beck B.R., Frösner G., Hunt M., Herzog C. Successful memory response following a booster dose with a virosome-formulated hepatitis A vaccine delayed up to 11 years. Clin Vaccine Immunol 2011, 18:885-887.